{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:53:18Z","timestamp":1790635998633,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1010183","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000}}],"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI139290"],"award-info":[{"award-number":["R01 AI139290"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX003860"],"award-info":[{"award-number":["I01BX003860"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["352417"],"award-info":[{"award-number":["352417"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI148379"],"award-info":[{"award-number":["R01 AI148379"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6BX004607"],"award-info":[{"award-number":["IK6BX004607"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["RCHS0235"],"award-info":[{"award-number":["RCHS0235"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PhD Fellowship"],"award-info":[{"award-number":["PhD Fellowship"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1 envelope. Antibodies against V3 also were inversely correlated with infection risk in subsets of vaccinees. Antibodies recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined the antiviral potential of poorly neutralizing monoclonal antibodies (mAbs) against immunodominant V1V2 and V3 sites by passive administration of human mAbs to humanized mice engrafted with CD34+ hematopoietic stem cells, followed by mucosal challenge with an HIV-1 infectious molecular clone expressing the envelope of a tier 2 resistant HIV-1 strain. Treatment with anti-V1V2 mAb 2158 or anti-V3 mAb 2219 did not prevent infection, but V3 mAb 2219 displayed a superior potency compared to V1V2 mAb 2158 in reducing virus burden. While these mAbs had no or weak neutralizing activity and elicited undetectable levels of antibody-dependent cellular cytotoxicity (ADCC), V3 mAb 2219 displayed a greater capacity to bind virus- and cell-associated HIV-1 envelope and to mediate antibody-dependent cellular phagocytosis (ADCP) and C1q complement binding as compared to V1V2 mAb 2158. Mutations in the Fc region of 2219 diminished these effector activities in vitro and lessened virus control in humanized mice. These results demonstrate the importance of Fc functions other than ADCC for antibodies without potent neutralizing activity.<\/jats:p>","DOI":"10.1371\/journal.ppat.1010183","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T13:38:24Z","timestamp":1641389904000},"page":"e1010183","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-9788","authenticated-orcid":true,"given":"Catarina E.","family":"Hioe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0621-6753","authenticated-orcid":true,"given":"Ourania","family":"Tsahouridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-9932","authenticated-orcid":true,"given":"J\u00e9romine","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-6782","authenticated-orcid":true,"given":"Roya","family":"Feyznezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Heindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-6202","authenticated-orcid":true,"given":"David A.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1570-6770","authenticated-orcid":true,"given":"Guangnan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Satija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Pr\u00e9vost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann J.","family":"Hessell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-8468","authenticated-orcid":true,"given":"Shixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-1997","authenticated-orcid":true,"given":"Benjamin K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zolla-Pazner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-1532","authenticated-orcid":true,"given":"Chitra","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"ppat.1010183.ref001","unstructured":"UNAIDS. Global HIV & AIDS statistics\u20142020 fact sheet 2020 [Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"issue":"23","key":"ppat.1010183.ref002","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"ppat.1010183.ref003","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"ppat.1010183.ref004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"JH Kim","year":"2015","journal-title":"Annu Rev Med"},{"issue":"1","key":"ppat.1010183.ref005","doi-asserted-by":"crossref","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 antibody responses induced in vaccinees in the ALVAC\/AIDSVAX HIV-1 vaccine efficacy trial","volume":"8","author":"S Zolla-Pazner","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"ppat.1010183.ref006","doi-asserted-by":"crossref","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"R Gottardo","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"ppat.1010183.ref007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ebiom.2014.10.022","article-title":"Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses","volume":"1","author":"S Zolla-Pazner","year":"2014","journal-title":"EBioMedicine"},{"issue":"228","key":"ppat.1010183.ref008","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"NL Yates","year":"2014","journal-title":"Sci Transl Med"},{"issue":"21","key":"ppat.1010183.ref009","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"M Bonsignori","year":"2012","journal-title":"J Virol"},{"issue":"4","key":"ppat.1010183.ref010","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology","volume":"163","author":"AW Chung","year":"2015","journal-title":"Cell"},{"issue":"11","key":"ppat.1010183.ref011","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1172\/JCI126391","article-title":"Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","volume":"129","author":"SD Neidich","year":"2019","journal-title":"J Clin Invest"},{"key":"ppat.1010183.ref012","first-page":"10","article-title":"Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1","author":"S Shangguan","year":"2021","journal-title":"Elife"},{"issue":"27","key":"ppat.1010183.ref013","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.1073\/pnas.1103012108","article-title":"Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody","volume":"108","author":"DR Burton","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1010183.ref014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mi.2013.23","article-title":"Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques","volume":"7","author":"C Moog","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"8","key":"ppat.1010183.ref015","doi-asserted-by":"crossref","first-page":"e1005042","DOI":"10.1371\/journal.ppat.1005042","article-title":"Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques","volume":"11","author":"S Santra","year":"2015","journal-title":"PLoS Pathog."},{"issue":"4","key":"ppat.1010183.ref016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cell.2017.06.048","article-title":"Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.","volume":"170","author":"JA Horwitz","year":"2017","journal-title":"Cell"},{"issue":"11","key":"ppat.1010183.ref017","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1128\/JVI.02095-05","article-title":"Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian\/human immunodeficiency virus infection","volume":"80","author":"Y Eda","year":"2006","journal-title":"J Virol"},{"issue":"11","key":"ppat.1010183.ref018","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02198-17","article-title":"Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian\/Human Immunodeficiency Virus Challenges","volume":"92","author":"AJ Hessell","year":"2018","journal-title":"J Virol"},{"issue":"15","key":"ppat.1010183.ref019","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1128\/JVI.00754-15","article-title":"The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel","volume":"89","author":"R Pan","year":"2015","journal-title":"J Virol"},{"issue":"7","key":"ppat.1010183.ref020","doi-asserted-by":"crossref","first-page":"e70859","DOI":"10.1371\/journal.pone.0070859","article-title":"Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.","volume":"8","author":"LM Mayr","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ppat.1010183.ref021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2012.02.003","article-title":"Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals","volume":"427","author":"MK Gorny","year":"2012","journal-title":"Virology"},{"issue":"8","key":"ppat.1010183.ref022","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1128\/JVI.03153-13","article-title":"Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV","volume":"88","author":"B Spurrier","year":"2014","journal-title":"J Virol"},{"issue":"10","key":"ppat.1010183.ref023","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.vaccine.2016.11.107","article-title":"Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination","volume":"35","author":"P Balasubramanian","year":"2017","journal-title":"Vaccine"},{"issue":"8","key":"ppat.1010183.ref024","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nsmb.1861","article-title":"Conserved structural elements in the V3 crown of HIV-1 gp120","volume":"17","author":"X Jiang","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"ppat.1010183.ref025","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1128\/JVI.00205-06","article-title":"Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity","volume":"80","author":"RL Stanfield","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"ppat.1010183.ref026","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.molimm.2015.04.011","article-title":"A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site","volume":"66","author":"L Li","year":"2015","journal-title":"Mol Immunol"},{"issue":"4","key":"ppat.1010183.ref027","doi-asserted-by":"crossref","first-page":"e10254","DOI":"10.1371\/journal.pone.0010254","article-title":"Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes","volume":"5","author":"CE Hioe","year":"2010","journal-title":"PLoS One"},{"issue":"14","key":"ppat.1010183.ref028","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1128\/JVI.02202-05","article-title":"Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1","volume":"80","author":"MK Gorny","year":"2006","journal-title":"J Virol"},{"issue":"18","key":"ppat.1010183.ref029","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1128\/JVI.76.18.9035-9045.2002","article-title":"Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades","volume":"76","author":"MK Gorny","year":"2002","journal-title":"J Virol"},{"issue":"39","key":"ppat.1010183.ref030","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1016\/j.vaccine.2010.12.052","article-title":"Quantitative assessment of masking of neutralization epitopes in HIV-1","volume":"29","author":"A Agarwal","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"ppat.1010183.ref031","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41598-017-18863-0","article-title":"Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials","volume":"8","author":"P Balasubramanian","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"ppat.1010183.ref032","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"S Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"ppat.1010183.ref033","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"N Karasavvas","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"310","key":"ppat.1010183.ref034","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"L Corey","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"ppat.1010183.ref035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1086\/339012","article-title":"Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes","volume":"185","author":"MD Roth","year":"2002","journal-title":"J Infect Dis"},{"issue":"3","key":"ppat.1010183.ref036","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/JVI.73.3.1974-1979.1999","article-title":"Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins","volume":"73","author":"A Gigler","year":"1999","journal-title":"J Virol"},{"issue":"4","key":"ppat.1010183.ref037","doi-asserted-by":"crossref","first-page":"e88226","DOI":"10.1172\/jci.insight.88226","article-title":"Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG","volume":"2","author":"RA Alvarez","year":"2017","journal-title":"JCI Insight."},{"issue":"23","key":"ppat.1010183.ref038","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies","volume":"78","author":"JM Binley","year":"2004","journal-title":"J Virol"},{"issue":"21","key":"ppat.1010183.ref039","doi-asserted-by":"crossref","first-page":"12853","DOI":"10.1128\/JVI.02125-14","article-title":"Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope","volume":"88","author":"C Upadhyay","year":"2014","journal-title":"J Virol"},{"key":"ppat.1010183.ref040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses","volume":"10","author":"MZ Tay","year":"2019","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"ppat.1010183.ref041","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"ME Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"issue":"17","key":"ppat.1010183.ref042","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/QAD.0000000000002011","article-title":"Antibody-dependent cellular cytotoxicity in HIV infection","volume":"32","author":"DN Forthal","year":"2018","journal-title":"AIDS"},{"issue":"4","key":"ppat.1010183.ref043","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tim.2017.10.007","article-title":"Impact of HIV-1 Envelope Conformation on ADCC Responses","volume":"26","author":"J Richard","year":"2018","journal-title":"Trends Microbiol"},{"issue":"17","key":"ppat.1010183.ref044","article-title":"Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.","volume":"91","author":"RLR Powell","year":"2017","journal-title":"J Virol"},{"issue":"24","key":"ppat.1010183.ref045","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1","volume":"75","author":"M Hezareh","year":"2001","journal-title":"J Virol"},{"issue":"7158","key":"ppat.1010183.ref046","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"AJ Hessell","year":"2007","journal-title":"Nature"},{"issue":"6","key":"ppat.1010183.ref047","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"S Bournazos","year":"2014","journal-title":"Cell"},{"issue":"1","key":"ppat.1010183.ref048","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","author":"MS Parsons","year":"2019","journal-title":"J Clin Invest"},{"issue":"585","key":"ppat.1010183.ref049","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates.","volume":"13","author":"L Hangartner","year":"2021","journal-title":"Sci Transl Med."},{"key":"ppat.1010183.ref050","doi-asserted-by":"crossref","first-page":"103518","DOI":"10.1016\/j.ebiom.2021.103518","article-title":"Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure","volume":"70","author":"MS Parsons","year":"2021","journal-title":"EBioMedicine"},{"issue":"17","key":"ppat.1010183.ref051","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/QAD.0000000000000444","article-title":"Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function","volume":"28","author":"AW Chung","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"ppat.1010183.ref052","first-page":"12655","article-title":"-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity","volume":"7","author":"LM Mayr","year":"2017","journal-title":"NonSci Rep"},{"issue":"5","key":"ppat.1010183.ref053","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JVI.03230-13","article-title":"Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity","volume":"88","author":"M Veillette","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"ppat.1010183.ref054","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JVI.02868-14","article-title":"The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals","volume":"89","author":"M Veillette","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"ppat.1010183.ref055","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1128\/JVI.02973-15","article-title":"Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity","volume":"90","author":"N Alsahafi","year":"2015","journal-title":"J Virol"},{"issue":"13","key":"ppat.1010183.ref056","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00484-18","article-title":"Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses","volume":"92","author":"J Prevost","year":"2018","journal-title":"J Virol"},{"issue":"17","key":"ppat.1010183.ref057","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1073\/pnas.1321507111","article-title":"Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity","volume":"111","author":"JF Arias","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"ppat.1010183.ref058","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jix547","article-title":"Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate-Dependent Mechanisms in Humanized Mice In Vivo","volume":"216","author":"G Li","year":"2017","journal-title":"J Infect Dis"},{"issue":"7","key":"ppat.1010183.ref059","doi-asserted-by":"crossref","first-page":"e1006505","DOI":"10.1371\/journal.ppat.1006505","article-title":"HIV-1 infection depletes human CD34+CD38- hematopoietic progenitor cells via pDC-dependent mechanisms","volume":"13","author":"G Li","year":"2017","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1010183.ref060","doi-asserted-by":"crossref","first-page":"e1006819","DOI":"10.1371\/journal.ppat.1006819","article-title":"Infection and depletion of CD4+ group-1 innate lymphoid cells by HIV-1 via type-I interferon pathway.","volume":"14","author":"J Zhao","year":"2018","journal-title":"PLoS Pathog."},{"key":"ppat.1010183.ref061","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/srep05845","article-title":"Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcgammaRIIa independent mechanism and do not diminish cytokines production","volume":"4","author":"A Lederle","year":"2014","journal-title":"Sci Rep"},{"key":"ppat.1010183.ref062","article-title":"Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates","author":"JCC Lorenzi","year":"2020","journal-title":"J Virol"},{"issue":"5","key":"ppat.1010183.ref063","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"YZ Cohen","year":"2018","journal-title":"J Virol"},{"issue":"9","key":"ppat.1010183.ref064","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1086\/429411","article-title":"Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda","volume":"191","author":"MJ Wawer","year":"2005","journal-title":"J Infect Dis"},{"issue":"5","key":"ppat.1010183.ref065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/590501","article-title":"HIV-1 transmission, by stage of infection","volume":"198","author":"TD Hollingsworth","year":"2008","journal-title":"J Infect Dis"},{"issue":"3","key":"ppat.1010183.ref066","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/jir747","article-title":"Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples","volume":"205","author":"JP Hughes","year":"2012","journal-title":"J Infect Dis"},{"key":"ppat.1010183.ref067","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3389\/fimmu.2019.01606","article-title":"Illuminating the Role of Vpr in HIV Infection of Myeloid Cells","volume":"10","author":"SB Nodder","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"ppat.1010183.ref068","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/diab.42.11.1574","article-title":"Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice","volume":"42","author":"AG Baxter","year":"1993","journal-title":"Diabetes"},{"key":"ppat.1010183.ref069","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fimmu.2018.00817","article-title":"Humanized Mice Engrafted With Human HSC Only or HSC and Thymus Support Comparable HIV-1 Replication, Immunopathology, and Responses to ART and Immune Therapy.","volume":"9","author":"L Cheng","year":"2018","journal-title":"Front Immunol"},{"key":"ppat.1010183.ref070","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3389\/fimmu.2018.02441","article-title":"Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines","volume":"9","author":"CE Hioe","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"ppat.1010183.ref071","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2006.02.032","article-title":"Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.","volume":"350","author":"S Wang","year":"2006","journal-title":"Virology"},{"issue":"12","key":"ppat.1010183.ref072","doi-asserted-by":"crossref","first-page":"e1009185","DOI":"10.1371\/journal.ppat.1009185","article-title":"Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes","volume":"16","author":"C Upadhyay","year":"2020","journal-title":"PLoS Pathog"},{"issue":"22","key":"ppat.1010183.ref073","doi-asserted-by":"crossref","first-page":"10362","DOI":"10.1128\/JVI.01458-16","article-title":"Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001","volume":"90","author":"MR Costa","year":"2016","journal-title":"J Virol"},{"issue":"6","key":"ppat.1010183.ref074","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.4049\/jimmunol.2001010","article-title":"Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone","volume":"206","author":"AJ Hessell","year":"2021","journal-title":"J Immunol"},{"issue":"10","key":"ppat.1010183.ref075","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/infdis\/jiaa531","article-title":"A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"222","author":"S Weiss","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"ppat.1010183.ref076","doi-asserted-by":"crossref","first-page":"e0180720","DOI":"10.1371\/journal.pone.0180720","article-title":"V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144","volume":"12","author":"LG Perez","year":"2017","journal-title":"PLoS One."},{"issue":"4","key":"ppat.1010183.ref077","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.chom.2019.03.002","article-title":"An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity","volume":"25","author":"N Alsahafi","year":"2019","journal-title":"Cell Host Microbe"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1010183","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T15:33:44Z","timestamp":1642520024000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010183"}},"subtitle":[],"editor":[{"given":"Daniel C.","family":"Douek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010183","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.24.445493","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}